RetaCagri Reconstitution: Pre-Mixed & Separate Vial Math

The retatrutide+cagrilintide stack (blend overview) reconstitutes either as two separate vials or as a single pre-mixed vial at a fixed 5:1 retatrutide:cagrilintide ratio. The math differs slightly between formats; the underlying reconstitution principles (sterile technique, swirling not shaking, refrigerated storage post-reconstitution, 4-week stability window) are the same as for any GLP-1 class peptide.

Research-context information only. Retatrutide and cagrilintide are both investigational drugs not approved by the FDA. The combination has not been formally tested in any published clinical trial. Reconstitution and storage protocols described below come from per-compound trial-protocol documentation and self-organized community references. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.

This guide is the practical mixing reference for both formats: what BAC water volumes are most-described in community protocols, what insulin-syringe units those produce at common community doses, and the storage rules that apply once the powder is in solution.

This article does not prescribe doses. It documents what reconstitution math the published trial protocols and community references use. Per-cycle dose decisions belong with a licensed physician.

New to bacteriostatic water? Start with what it is, how much to use per vial, and how long it lasts — or see the full Bacteriostatic Water Guide.

What You Need

For either format:

• Lyophilized peptide vial(s) — separate retatrutide + cagrilintide, or one pre-mixed reta+cagri blend
• Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol preservative
• 30 mL syringe with 22-gauge needle for transferring BAC water
• 100-unit insulin syringes (U-100) for individual draws
• Alcohol swabs for vial-stopper sterilization
• Sharps container for used needles
• Clean flat surface with hands washed

Pre-Mixed 12.5 / 2.5 mg Vial Reconstitution

The 12.5/2.5 mg vial holds 15 mg total peptide (12.5 mg retatrutide + 2.5 mg cagrilintide) in a 5:1 mass ratio. Most-referenced community reconstitution: 2 mL BAC water.

Documented Preparation Sequence

The most-referenced community preparation sequence for the 12.5/2.5 mg vial: hands washed, flat surface prepared with the unopened vial, BAC water, syringes, and alcohol swabs within reach; both stoppers sterilized with separate swabs; 2 mL BAC water drawn into a 30 mL transfer syringe; water injected slowly down the inside vial wall, not onto the lyophilized cake (which protects the peptide structure); vial swirled (not shaken) for 30–60 seconds, since shaking introduces foam that can denature the peptide; allowed to rest 1–2 minutes at room temperature until the solution is clear with no visible particulates; refrigerated at 2–8 °C until the next draw.

Concentration Math

Insulin Syringe Units (U-100, 100 units = 1 mL)

Yield at maintenance: at a 1.2 mg combined dose per week, the vial provides ~3 weeks of dosing (15 mg ÷ 1.2 mg/wk = 12.5 weeks at total mass, but draws of 16 units twice a week or 16 units once a week land at ~3 weeks of practical use given common dosing patterns).

Pre-Mixed 20 / 4 mg Vial Reconstitution

The 20/4 mg vial holds 24 mg total peptide (20 mg retatrutide + 4 mg cagrilintide) in the same 5:1 mass ratio. Most-referenced reconstitution: 3 mL BAC water.

Concentration Math

Insulin Syringe Units

Yield at maintenance: at a 1.2 mg combined dose per week, the 20/4 vial provides ~5 weeks of dosing — ~67% more than the 12.5/2.5 vial. Fewer reconstitution events per protocol cycle.

Separate-Vial Reconstitution (Titration-Compatible)

Separate vials are the format that matches the staged community titration cadence, where retatrutide is titrated first and cagrilintide is layered on its own 4-week-per-step ramp. Locked-ratio pre-mixed vials don't fit this phase.

Retatrutide 10 mg Vial

Most-referenced reconstitution: 2 mL BAC water → 5 mg/mL.

For step-by-step retatrutide reconstitution detail, see the Retatrutide Reconstitution Guide.

Cagrilintide 5 mg Vial

Most-referenced reconstitution: 2 mL BAC water → 2.5 mg/mL.

The 2.4 mg maintenance dose is close to the 1 mL capacity of a standard U-100 insulin syringe, which is why some community sources reconstitute cagrilintide at higher concentration (e.g., 5 mg in 1.5 mL → 3.33 mg/mL → 2.4 mg = 0.72 mL = 72 units) to keep dose volume manageable.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Storage Rules

Both retatrutide and cagrilintide are stable peptides with well-characterized storage profiles. The pre-mixed blend follows the same rules.

Community protocols and trial storage documentation describe avoiding freeze-thaw cycles on reconstituted vials — freeze-thaw cycles are the documented cause of peptide structure damage. The lyophilized form can be frozen; the reconstituted form is not.

Light protection is standard practice. Both peptides are not particularly photosensitive, but storing the reconstituted vial in its original carton or a dark area of the refrigerator is the conservative default.

Before each draw, community protocols describe checking the solution; cloudiness, particulates, or color change in a previously clear solution are cited as signs to discard and start a new vial.

Injection Technique — Same-Day, Separate-Site

The most-described community pattern for two-compound stacks is same-day, separate-site injection: both compounds delivered the same day each week, but at different subcutaneous sites. This concentrates peak GI effect on a single day rather than smearing nausea across the week.

For pre-mixed blend users, only one injection is needed — the site rotation pattern is the same as for retatrutide alone (abdomen, rotating).

Subcutaneous Injection Technique (Same for All Formats)

Community injection protocols document standard subcutaneous technique for this class of peptide: sterilizing the injection site; pinching a fold of subcutaneous tissue; inserting a U-100 insulin needle at 90° (or 45° in lean frames); injecting the drawn volume slowly over 5–10 seconds; holding the needle in place ~5 seconds before withdrawal; applying gentle pressure without rubbing; and disposing of the needle in a sharps container. First-time users are advised to review subcutaneous injection technique with a licensed healthcare provider before starting.

Common Errors and Fixes

Related Reading

• Retatrutide+Cagrilintide Stack Dosing Guide — Full titration math
• Retatrutide+Cagrilintide Stack Buying Guide — Pre-mixed vs separate vials, COA
• Retatrutide+Cagrilintide Stack Benefits — Quad-pathway mechanism
• Retatrutide+Cagrilintide Stack Side Effects — Combined GI burden
• Retatrutide+Cagrilintide Stack Results Timeline — Week-by-week
• Retatrutide Reconstitution Guide — Standalone retatrutide mixing
• Best Retatrutide+Cagrilintide Vendors — Ranked vendor comparison

For educational and research purposes only. This is not medical advice. Retatrutide and cagrilintide are investigational drugs without FDA approval; the combination has not been formally tested in any published clinical trial.